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Background: Growth hormone levels often decline on aging, and this “somatopause”
is associated with muscle and bone loss, visceral adiposity and impaired cardiovascular
function. Mercury has been detected in human pituitary glands, so to see if mercury could
play a part in the somatopause we measured the proportion of people at different ages
who had mercury in their anterior pituitary cells.
Materials and methods: Paraffin sections of pituitary glands taken at autopsy from
94 people between the ages of 2 and 99 years were stained for inorganic mercury
using autometallography. Pituitary mercury content was classified as none, low (<30% of
cells) or high (>30% of cells) in increasing two-decade age groups. Autometallography
combined with immunohistochemistry determined which hormone-producing cells
contained mercury. Laser ablation-inductively coupled plasma-mass spectrometry was
used to confirm the presence of mercury.
Results: The proportion of people with low-content pituitary mercury remained between
33 and 42% at all ages. The proportion of people with high-content mercury increased
with increasing age, from 0% of people in the 2–20 year group to a peak of 50% of
people in the 61–80 years group, followed by a fall to 35% of people in the 81–99
years group. Mercury, when present, was found always in somatotrophs, occasionally
in corticotrophs, rarely in thyrotrophs and gonadotrophs, and never in lactotrophs. Laser
ablation-inductively coupled plasma-mass spectrometry detected mercury in regions of
pituitaries that stained with autometallography.
Conclusions: The proportion of people with mercury in their anterior pituitary cells,
mostly somatotrophs, increases with aging, suggesting that mercury toxicity could be
one factor contributing to the decline in growth hormone levels found in advancing age.
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INTRODUCTION
In many people growth hormone levels decline with increasing age, a phenomenon termed
the somatopause (1–8). Although average growth hormone levels decrease on aging, values for
individuals at the same ages vary, so that 45% of people aged over 69 years still release growth
hormone normally (3). Obesity plays some role in the somatopause, but most factors behind the
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variability of growth hormone levels in aging remain unknown
(3). The somatopause is linked to several conditions associated
with aging, such as decreases in muscle mass, bone density,
and skin thickness, as well as cognitive and cardiovascular
dysfunction, frailty and falls, and visceral adiposity (9, 10).
Growth hormone replacement in older men ameliorates some of
these changes (4), but the value of growth hormone replacement
in the somatopause remains controversial (11–15). Finding some
of the factors underlying the somatopause could, however, be of
value in developing ways to prevent or treat declining levels of
growth hormone.
The rodent anterior pituitary readily takes up organic
mercury, which localizes to lysosomes and secretory granules
of somatotrophs (16). The primate anterior pituitary takes up
mercury vapor from exposure to as few as three dental mercury-
containing amalgam fillings, with the mercury again seen in
lysosomes and secretory granules of somatotrophs (17). In
humans, the anterior pituitary is a preferred organ for mercury
deposition (18), since mercury has been found in the anterior
pituitary by several workers (19–23), but which hormone-
producing pituitary cells contained the mercury was not able to
be established in these studies. Pituitary mercury levels correlate
with numbers of dental amalgam fillings (24–27), but the small
numbers and limited age ranges of people studied here did not
allow for age-related analyses.
To determine whether age-related accumulation of
mercury within the pituitary could play a part in causing
the somatopause, we examined pituitary glands from people
over a wide range of ages, using a histochemical technique
that detects intracellular mercury, and combined this with
hormone immunohistochemistry to see if human somatotrophs
preferentially take up mercury.
MATERIALS AND METHODS
Study Design
Autopsy reports between 1997 and 2014 from the New South
Wales Department of Forensic Medicine were filtered to include
a variety of clinicopathological conditions, such as cancer,
neurodegenerative diseases, and psychiatric disorders, as well as
people who died from sudden non-medical causes of death such
as drowning, suicide or trauma. Horizontally-sectioned pituitary
samples taken from 94 of these individuals (62 male and 32
female) (Table 1) were studied.
Ethics
The study was approved by the Human Research Committee,
Sydney Local Health District RPAH Zone, and by the Office of
the New South Wales Coroner. The institutional review board
waived the need for written informed consent from relatives of
individuals studied since this was a de-identified retrospective
study of autopsy tissue.
Autometallography
Seven-micron paraffin sections of the pituitary were stained
for inorganic mercury bound to sulfide or selenide using silver
nitrate autometallography, which represents the presence of
TABLE 1 | Ages, genders, major diagnoses, and causes of death in people with







2–20 Male None Drowning None
2–20 Male None Drowning None
2–20 Male None Drug OD None
2–20 Female None Trauma None
2–20 Female None Trauma None
2–20 Male None Drowning Low
2–20 Male Depression Suicide Low
2–20 Male None Suicide Low
2–20 Male None Suicide None
21–40 Female None Suicide High
21–40 Male None Suicide High
21–40 Male None Suicide High
21–40 Male None Cardiovascular None
21–40 Male None Drowning None
21–40 Male Schizophrenia Drug OD None
21–40 Male Schizophrenia Drug OD None
21–40 Female Epilepsy SUDEP None
21–40 Male Schizophrenia Unknown None
21–40 Male Obesity Cerebrovascular Low
21–40 Female None Drowning Low
21–40 Male None Drowning Low
21–40 Male None Drowning Low
21–40 Male None Drug OD Low
21–40 Male None Suicide Low
21–40 Male Depression Suicide Low
21–40 Female Schizophrenia Suicide Low
21–40 Female Anorexia nervosa Undernutrition Low
21–40 Female None Drowning High
21–40 Male Schizophrenia SUDEP High
21–40 Male Schizophrenia Suicide Low
21–40 Male None Suicide Low
21–40 Male None Suicide None
21–40 Male None Suicide None
21–40 Male None Suicide None
21–40 Male None Suicide None
41–60 Male None Suicide High
41–60 Male None Suicide High
41–60 Female None Suicide High
41–60 Male None Suicide High
41–60 Male None Suicide Low
41–60 Male Obesity Cardiovascular None
41–60 Male Schizophrenia Drug OD None
41–60 Male Schizophrenia Drug OD None
41–60 Male Schizophrenia Respiratory None
41–60 Female Schizophrenia Suicide Low
41–60 Male Bipolar Trauma None
41–60 Male None Cancer Low
41–60 Female Schizophrenia Cirrhosis Low
41–60 Male None Drowning Low
(Continued)
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41–60 Male None Drug OD Low
41–60 Male Schizophrenia Drug OD Low
41–60 Male None Trauma Low
41–60 Female None Trauma Low
41–60 Male Schizophrenia Unknown Low
41–60 Female None Drowning High
41–60 Female None Drowning High
41–60 Female Bipolar Drug OD High
41–60 Male Obesity Drug OD High
41–60 Male MSA Unknown High
41–60 Male None Suicide None
41–60 Male None Suicide None
61–80 Male Depression Suicide Low
61–80 Male None Suicide Low
61–80 Male Alzheimer Drowning None
61–80 Female Alzheimer Infection None
61–80 Female Parkinson Asphyxia Low
61–80 Male Parkinson Cardiovascular Low
61–80 Male MSA Choking Low
61–80 Male Obesity Trauma Low
61–80 Female Parkinson Cardiovascular High
61–80 Male MSA Choking High
61–80 Female None Drowning High
61–80 Male None Drowning High
61–80 Female Parkinson Infection High
61–80 Female Parkinson Trauma High
61–80 Female None Trauma High
61–80 Male None Trauma High
81–99 Female None Cardiovascular None
81–99 Female Alzheimer Cardiovascular None
81–99 Male Dementia NOS Cardiovascular None
81–99 Female Lewy body disease Infection None
81–99 Male None Trauma None
81–99 Female None Cardiovascular Low
81–99 Female None Cardiovascular Low
81–99 Male None Cardiovascular Low
81–99 Female Alzheimer Cardiovascular Low
81–99 Male Parkinson Infection Low
81–99 Male Alzheimer Trauma Low
81–99 Female None Cardiovascular High
81–99 Female Parkinson Cardiovascular High
81–99 Male PSP Cardiovascular High
81–99 Male Lewy body disease Cerebrovascular High
81–99 Female Alzheimer Infection High
81–99 Female Alzheimer Infection High
OD, overdose; MSA, multiple system atrophy; NOS, not otherwise specified; PSP,
progressive supranuclear palsy; SUDEP, sudden unexpected death in epilepsy.
mercury as black grains (28). Autometallography is a sensitive
photographic technique that can detect as few as 10 mercury
sulfide/selenide molecules in a cell (29). Briefly, sections were
FIGURE 1 | Mercury-positive control section for autometallography. In a
mouse given intraperitoneal mercuric chloride, mercury is seen as multiple
black granules (e.g., arrow) in the cytoplasm of spinal anterior horn motor
neurons. Autometallography/hematoxylin.
placed in physical developer containing 50% gum arabic, citrate
buffer, hydroquinone, and silver nitrate at 26◦C for 80min in
the dark then washed in 5% sodium thiosulphate to remove
unbound silver. Sections were counterstained with mercury-
free hematoxylin and viewed with bright-field microscopy. Each
staining run included a control section of mouse spinal cord
where motor neuron cell bodies contained mercury (Figure 1)
following an intraperitoneal injection of mercuric chloride (30).
Sections were also stained with hematoxylin only to act as a
control, and hematoxylin and eosin to assess histopathology. Of
note, the semi-quantitative use of autometallography (modified
to detect zinc) has been used previously in relation to endocrine
studies of insulin and glucose levels (31).
Mercury Content of the Pituitary
The proportion of pituitary cells containing mercury was
estimated by counting the number of cells containing
mercury (defined as cells with two or more cytoplasmic
autometallography grains) within a 10× 10 eyepiece grid viewed
at a magnification of 200×, covering an area of 1 × 1mm,
which was stepped through the pituitary. Mercury content
within the anterior pituitary was categorized as being “none” if
no mercury-containing cells were seen, “low” if mercury was
present in fewer than 30% of cells throughout the pituitary, and
“high” if, in at least four regions, mercury was present in more
than 30% of cells.
Pituitary Hormone Immunostaining
To find which particular hormone-producing pituitary cells
contained mercury, after autometallography staining 11
pituitaries known to contain mercury were immunostained
with mouse anti-human antibodies to growth hormone 1:2,000
(polyclonal, Dako), adrenocorticotropic hormone 1:250 (clone
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02A3, Dako), thyroid stimulating hormone 1:100 (clone 42,
Dako), prolactin 1:500 (polyclonal, Cell Marque), luteinising
hormone 1:20,000 (polyclonal, Dako), and follicle stimulating
hormone 1:200 (clone C10, Dako). Visualization was with Bond
Polymer Refine Red Detection (Leica) so as not to obscure the
black mercury grains. The proportion of each type of hormone-
containing pituitary cell that contained mercury was graded into




In addition to inorganic mercury, autometallography can stain
inorganic silver, bismuth, and gold (28, 32). Therefore, to confirm
that autometallography staining in pituitary cells was due to
mercury, seven-micron paraffin sections of selected pituitaries,
in which regional differences in autometallography staining were
marked, were deparaffinised and subjected to LA-ICP-MS for
mercury, silver, bismuth, and gold. In two pituitaries LA-ICP-MS
was used to look for aluminum, cadmium and lead, as well as
the above metals. An NWR193 excimer laser (Kenelec Scientific)
was hyphenated to an Agilent Technologies 7700 ICP-MS fitted
with “s” lenses for enhanced sensitivity, with argon used as the
carrier gas. LA-ICP-MS conditions were optimized on NIST 612
Trace Element in Glass CRM and the sample was ablated with a
55µm spot size and a scan speed of 220µm s−1 at a frequency
of 20Hz. The data were collated into a single image file using
in-house developed software and visualized using FIJI. Limits of
detection using LA-ICP-MS were estimated to be between 0.05
and 0.81 µg g−1 (33).
Statistics
GraphPad Prism 8 software was used for chi-square tests for
trend to analyse the proportion of people with any mercury in
their pituitary in relation to age. Significance was assessed at the
0.05 level.
RESULTS
Mercury in Pituitary Cells
Mercury-positive autometallography staining of pituitary cells
was seen as multiple small round black grains of varying size
within the cytoplasm (Figure 2). The distribution of mercury-
containing cells within the pituitary could be widespread
or regional, often with preference for the lateral lobes. The
percentage of pituitary samples in eachmercury-content category
(Figure 3) was 32% for no mercury, 38% for low mercury, and
30% for high mercury. No autometallography staining was seen
in the posterior pituitary, no black grains were seen in sections
stained with hematoxylin alone, and no incidental pathology was
present in any of the pituitary samples.
Proportion of People at Different Ages With
Mercury in Their Pituitary Glands
Mercury (either low or high content) was seen in the anterior
pituitary in 33% of people in the 2–20 years group (N = 9), 62% in
the 21–40 years group (N = 26), 73% in the 41–60 years group (N
FIGURE 2 | Mercury in anterior pituitary cells. Mercury is seen as multiple
small black autometallography-stained foci of varying size within the pale
cytoplasm of cells (e.g., solid arrows), surrounding the blue-stained nuclei. A
small blood vessel with pale yellow erythrocytes is present (open arrow).
Autometallography/hematoxylin.
= 26), 88% in the 61–80 years group (N = 16), and 71% of people
in the 81–99 years group (N = 17) (Figure 3). The proportion of
people with low-content pituitary mercury remained between 33
and 42% at all ages. The proportion of people with high-content
mercury increased with increasing age, from 0% of people in the
2–20 years group to a peak of 50% of people in the 61–80 years
group, followed by a fall to 35% of people in the 81–99 years
group (Figure 4). The overall increase in the proportion of people
on aging who had any mercury in their pituitaries was significant
(chi-square trend for aging 4.5, p = 0.034). The youngest person
to have pituitary mercury was aged 16 years.
The 32 females in the study had a greater proportion (78%) of
mercury in their pituitaries than the 62 males (55%), probably
because females were older on average (mean age 63 years,
age range 2–99 years, SD 28 years) than males (mean age 47
years, age range 2–96 years, SD 23 years). The numbers of
people with mercury in their pituitary cells did not appear
to be markedly higher for any individual clinicopathological
condition or cause of death (Table 1), though numbers in each
diagnostic group within two-decade age ranges were too small
for statistical comparisons.
Combined Autometallography and Pituitary
Hormone Immunostaining
The usual geographic predominance of the different pituitary
hormone-containing cells was found in the 11 pituitaries
studied with immunostaining, i.e., somatotrophs in the lateral
lobes, corticotrophs in the central area, thyrotrophs in the
central anterior area, lactotrophs in the posterolateral areas,
and gonadotrophs widely dispersed. In the eight people
with high-content pituitary mercury, the mercury was seen
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FIGURE 3 | No, low or high mercury content in the anterior pituitary. (A) No mercury (i.e., no autometallography staining) is present in this pituitary. (B) Low mercury
content (autometallography grains in fewer than 30% of cells) of the pituitary is seen in this pituitary. (C) High mercury content (more than 30% of cells containing
autometallography grains) is present in this pituitary. Numerous small blood vessels (with yellow-colored erythrocytes) are present in all pituitaries.
Autometallography/hematoxylin.
FIGURE 4 | Proportion of people at increasing ages with pituitaries containing
mercury. Low-content mercury (yellow bars) is present in similar proportions of
people (between 33 and 42%) over all age ranges. High-content mercury (red
bars) starts appearing in the 21–40 years group, then increases with
advancing age to reach a peak of 50% of people in the 61–80 years group,
before dropping back in the final 81–99 years group. Numbers of people in
each group are given above the bars.
in many growth hormone-immunostained somatotrophs
(Figure 5), in occasional immunostained corticotrophs and
thyrotrophs, in rare immunostained gonadotrophs, but not
FIGURE 5 | Mercury in pituitary immunostained somatotrophs. Mercury is
seen as clusters of round black grains in the red-immunostained cytoplasm of
somatotrophs (e.g., closed arrows). Cells not containing growth hormone
(e.g., open arrows) do not contain mercury. Autometallography/hematoxylin
combined with growth hormone immunostaining.
in immunostained lactotrophs (Table 2). In the three people
with low-content pituitary mercury, the mercury was seen
in occasional somatotrophs, in rare corticotrophs, but not in
thyrotrophs, gonadotrophs, or lactotrophs. The intensity of
immunostaining was similar in cells with and without mercury,
indicating that the autometallography process itself did not
interfere with the immunostaining.
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TABLE 2 | Proportion of pituitary hormone-immunostained cells containing mercury.
Age (year) Pituitary mercury content GH ACTH TSH LH FSH PROL
30 High +++ + + + 0 0
44 High +++ + 0 + + 0
46 High +++ + + 0 0 0
48 High +++ ++ + 0 0 0
49 High +++ + 0 0 0 0
59 High +++ + 0 0 0 0
72 High +++ ++ + + 0 0
95 High +++ ++ 0 0 0 0
29 Low ++ 0 0 0 0 0
36 Low ++ + 0 0 0 0
38 Low ++ 0 0 0 0 0
0, 0% (none); +, 1–5% (rare); ++, 6–30% (occasional); +++, >30% (common).
Correlation of Autometallography With
Laser Ablation-Inductively Coupled
Plasma-Mass Spectrometry (LA-ICP-MS)
LA-ICP-MS of the pituitaries of a 16 years-old male with low-
content autometallography mercury, and a 75 years-old male and
a 44 years-old female both with high-content autometallography
mercury, confirmed that autometallography staining in different
regions of the pituitary was due to the presence of mercury
(Figure 6). No significant amounts of the other metals that can be
detected with autometallography, i.e., inorganic silver, bismuth,
and gold, were seen on LA-ICP-MS. No LA-ICP-MS mercury
was found in a 78 years-old woman with no autometallography
staining of the pituitary. No significant accumulation of pituitary
aluminum, cadmium, or lead was seen.
DISCUSSION
Key findings of this study were that mercury accumulates
over time in human pituitary cells, and that the cells that
predominantly contain mercury are the growth hormone-
containing somatotrophs. Up to fifty percent of older adults
have pituitaries with a high content of mercury, which is
approximately the same proportion of older adults who have
reduced secretion of growth hormone (3). These findings indicate
that mercury is a candidate for an environmental toxin that
causes the reduced growth hormone levels of the somatopause.
The major physical forms of mercury are mercury vapor,
methylmercury, andmercuric ions, the latter being the proximate
toxic intracellular form of the metal (34). Exposure to all these
three forms of mercury results in detectable levels of mercury
in the pituitary (16, 27, 35). Humans are usually exposed
to mercury either as methylmercury from eating mercury-
containing fish, or mercury vapor from occupational exposures
or dental amalgam restorations.
The reason somatotrophs preferentially take upmercury is not
clear. The pituitary may be predisposed to taking up circulating
toxins such as mercury because of its rich blood supply, and
because, unlike the brain, it does not have endothelial tight
junctions to prevent the entry of these metals. Mercury vapor
crosses cell membranes readily and is oxidized to ionic mercury
by the intracellular catalase-hydrogen peroxide pathway, so that
cells rich in these enzymes are more likely to trap mercuric
ions within the cell (34). Methylmercury crosses cell membranes
and is then slowly demethylated in the cell into mercuric ions.
Mercury is transported actively into cells of the kidney, liver,
intestine, and placenta (36), and somatotrophs may have similar
as-yet unknown active transport mechanisms for mercury.
Corticotrophs, thyrotrophs, and gonadotrophs in our study that
occasionally contained mercury are cells known to co-express
growth hormone (37), so the presence of some growth hormone
in a cell may be a clue that it is susceptible to the entry of mercury.
Mercury damages cells via the generation of oxygen radicals,
binding to membranous organelles such as mitochondria,
binding to sulfhydryl-containing proteins, promoting
autoimmunity, and causing genetic or epigenetic changes
(18, 38). The extensive immunostaining of growth hormone
in cells that contained large amount of mercury indicate that
growth hormone production in these somatotrophs appears
intact, so a deleterious effect of mercury on growth hormone
secretion, rather than production, appears likely. Lysosomes
store intracellular toxicants such as mercury, and mercury is
located within lysosomes in the pituitary cells of rats exposed
to mercury as seen on electron microscopy (16, 35, 39). The
distribution of mercury in our human pituitary cells suggests
that mercury is also within lysosomes, though this could
not be confirmed using electron microscopy because of the
method of tissue processing. Mercury accumulation in rodent
somatotrophs causes vacuolation of lysosomes, indicating
disruption to their structure (16). A build-up of mercury
within lysosomes could disturb their many functions, which,
as well as autophagy, include cell signaling and metabolic
roles (40). Although lysosomal damage seems a likely cause of
decreased growth hormone secretion in mercury-containing
somatotrophs, mercury also binds to pituitary cell secretory
granules (16, 35, 39), another way in which mercury could
inhibit growth hormone secretion.
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FIGURE 6 | Correlation of autometallography with LA-ICP-MS. The regions of two pituitaries scanned with LA-ICP-MS are within the boxes on the left. (A) LA-ICP-MS
image from a 16-years old male shows minimal mercury (green) on the upper right (B box region), correlating with (B) negative autometallography staining for mercury
in this region. LA-ICP-MS high mercury levels (red and yellow) are present on the lower right of this pituitary (C box region) (LA-ICP-MS intensity scale in counts
per second), correlating with (C) finely-dispersed autometallography staining here. (D) LA-ICP-MS image from a 75 years-old male shows minimal mercury
(green/blue) on the upper right (E box region), corresponding to (E) pituitary cells containing sparse autometallography grains here. Large clusters of LA-ICP-MS
mercury (yellow/red) are scattered within the left and lower regions of this pituitary (e.g., F box region), corresponding to (F) the dense autometallography grains in
pituitary cells here. Note the higher numbers of counts per second for each color level in this pituitary. Hematoxylin and eosin on the two sections on the left.
Autometallography/hematoxylin on B, C, E, and F, bars = 20µm.
The physiological effects of mercury on human growth
hormone secretion is not yet known. A variety of pituitary
hormones have been measured in different groups of people
occupationally exposed to mercury (41), but none of these
included growth hormone levels, probably because of the
challenges in analyzing the diurnal and nocturnal fluctuations
in growth hormone secretion (3). Analyses of growth hormone
secretion in experimental animals exposed to mercury may cast
light on this issue.
Growth hormone causes an increase in lean body mass and a
decrease in adipose mass, and visceral adiposity is a key feature
of the somatopause (42). The amount of visceral adipose tissue
is associated with blood mercury concentration (43), but the
reason for this is not known. Our findings suggest the link could
be mercury in somatotrophs decreasing the secretion of growth
hormone, with consequent re-partitioning of adipose tissue to the
visceral compartment.
The increase in the proportion of people with high-content
pituitary mercury peaked in the 61–80 years group, but then
fell back in the oldest 81–99 years group. We found a similar
decrease in the proportion of people who had toxic metals in
their locus ceruleus in the oldest age group (44). These findings
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could be due to a “survivor” effect, in which people who live to
advanced ages are less likely to have been exposed to high levels
of environmental toxins, with consequent deleterious effects on
health. This survivor effect has been suggested to be a reason
for the reduced incidence in advanced age of Alzheimer disease,
Parkinson disease, and amyotrophic lateral sclerosis, disorders
that have been associated with exposure to toxic metals, as well
as for the plateau of mortality in later life (44).
This study has several limitations (1) This was a retrospective
study of pituitaries sampled at coronial autopsy, so we do
not have details of possible mercury exposure during life, e.g.,
frequency and type of fish consumption, numbers of occlusal
amalgam restorations, and lifetime occupations. (2) It is difficult
to obtain enough human pituitary autopsy samples, together
with detailed clinical data and biochemical analyses of growth
hormone secretion, to allow a comprehensive examination of
the effects of mercury on growth hormone levels throughout
life. Ideally, an ambulant population in whom pituitary mercury
could be estimated by a future non-invasive technique, and
in whom growth hormone levels could be measured, would
be studied. (3) Pituitaries were not sampled at the same
horizontal level, and mercury distribution in pituitaries was
often patchy, so no formal quantification of total numbers
of pituitary cells containing mercury was attempted. (4) LA-
ICP-MS was unable to be undertaken on all pituitaries, so we
cannot say with certainty that autometallography demonstrated
mercury in all individuals. However, a previous study using
LA-ICP-MS indicated that autometallography in human tissue
most likely shows the presence of mercury (44). (5) The
youngest age at which pituitary mercury was found in our study
was 16 years, but we were not able to accurately determine
at what age pituitary mercury first starts to appear, since
numbers in the 2–20 years group were relatively small, and
the three people with pituitary mercury were all in the second
decade of life. (6) Autometallography demonstrates inorganic
mercury that is bound to sulfides and selenides, but not
organic mercury. However, inorganic mercury is considered
to be the proximate toxic form of the metal in tissues (34)
and is therefore the most important type to measure. (7)
Post mortem intervals are seldom able to be determined
accurately in coronial autopsies. We did not therefore attempt
to detect types of cell damage or death, such as apoptosis or
free radical generation, that have been described in mercury
toxicity. However, these mechanisms could be sought in rodent
models since mercury accumulation in the rat pituitary is well
described (16).
In conclusion, we propose that mercury in pituitary
somatotrophs plays a part in the age-related decline of growth
hormone that is found in many people. The amount of mercury
in the atmosphere is increasing steadily, due mostly to the
burning of fossil fuels (45), and this mercury enters the global
atmosphere-water-soil cycle. Therefore, if mercury exposure
does cause decreased growth hormone secretion, the numbers
of people suffering from effects of the somatopause can be
expected to increase in future years. Although there is as yet no
unequivocal link between mercury in the somatopause, it would
seem prudent to limit consumption of high-mercury predatory
fish such as shark and swordfish, maintain strict workplace
protections against mercury exposure, consider alternatives to
the placement of mercury-containing amalgam fillings, and
ensure that the diet contains enough selenium to help counteract
any toxic effects of mercury (46).
DATA AVAILABILITY
All datasets generated for this study are included in the
manuscript and/or the supplementary files.
ETHICS STATEMENT
The study was approved by the Human Research Committee,
Sydney Local Health District RPAH Zone, and by the Office of
the New South Wales Coroner. The institutional review board
waived the need for written informed consent from relatives of
individuals studied since this was a de-identified retrospective
study of autopsy tissue.
AUTHOR CONTRIBUTIONS
RP conceived and planned the study and drafted the manuscript.
RP, SK, DB, and PD performed the experiments and analyzed the
data. All authors revised and approved the article.
FUNDING
RP is supported by the Aimee StacyMemorial and Ignacy Burnett
bequests. DB is supported by an Australian Research Council
Discovery Early Career Researcher Award DE180100194. PD
is supported by Australian Research Council Discovery Project
Grants DP170100036 and DP190102361. Mr. Ki Lam performed
the immunostaining in the Department of Tissue Pathology and
Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney.
REFERENCES
1. Carlson HE, Gillin JC, Gorden P, Snyder F. Abscence of sleep-related
growth hormone peaks in aged normal subjects and in acromegaly.
J Clin Endocrinol Metab. (1972) 34:1102–5. doi: 10.1210/jcem-34-
6-1102
2. Finkelstein JW, Roffwarg HP, Boyar RM, Kream J, Hellman L. Age-
related change in the twenty-four-hour spontaneous secretion of growth
hormone. J Clin Endocrinol Metab. (1972) 35:665–70. doi: 10.1210/jcem-35-
5-665
3. Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA, Bain RP.
Impaired growth hormone secretion in the adult population: relation to age
and adiposity. J Clin Invest. (1981) 67:1361–9. doi: 10.1172/JCI110164
4. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, et al.
Effects of human growth hormone in men over 60 years old. N Engl J Med.
(1990) 323:1–6. doi: 10.1056/NEJM199007053230101
Frontiers in Endocrinology | www.frontiersin.org 8 June 2019 | Volume 10 | Article 419
Pamphlett et al. Mercury in Aging Pituitary Somatotrophs
5. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are
specific negative determinants of the frequency and amplitude of growth
hormone (GH) secretory bursts and the half-life of endogenous GH in healthy
men. J Clin Endocrinol Metab. (1991) 73:1081–8. doi: 10.1210/jcem-73-5-1081
6. Veldhuis JD, Liem AY, South S, Weltman A, Weltman J, Clemmons DA,
et al. Differential impact of age, sex steroid hormones, and obesity on
basal versus pulsatile growth hormone secretion in men as assessed in an
ultrasensitive chemiluminescence assay. J Clin Endocrinol Metab. (1995)
80:3209–22. doi: 10.1210/jcem.80.11.7593428
7. Veldhuis JD, Iranmanesh A, Lizarralde G, Urban RJ. Combined deficits in
the somatotropic and gonadotropic axes in healthy aging men: an appraisal
of neuroendocrine mechanisms by deconvolution analysis. Neurobiol Aging.
(1994) 15:509–17. doi: 10.1016/0197-4580(94)90089-2
8. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth
hormone secretion in experimental animals and the human. Endocr Rev.
(1998) 19:717–97. doi: 10.1210/er.19.6.717
9. Rudman D. Growth hormone, body composition, and aging. J
Am Geriatr Soc. (1985) 33:800–7. doi: 10.1111/j.1532-5415.1985.tb0
4195.x
10. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons
D, et al. Growth hormone deficiency in adulthood and the effects
of growth hormone replacement: a review. Growth Hormone Research
Society Scientific Committee. J Clin Endocrinol Metab. (1998) 83:382–95.
doi: 10.1210/jcem.83.2.4594
11. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML.
Evaluation and treatment of adult growth hormone deficiency: an Endocrine
Society clinical practice guideline. J Clin Endocrinol Metab. (2011) 96:1587–
609. doi: 10.1210/jc.2011-0179
12. Sattler FR. Growth hormone in the aging male. Best Pract Res
Clin Endocrinol Metab. (2013) 27:541–55. doi: 10.1016/j.beem.2013.
05.003
13. Sonksen P. Idiopathic growth hormone deficiency in adults, Ben Johnson
and the somatopause. J Clin Endocrinol Metab. (2013) 98:2270–3.
doi: 10.1210/jc.2013-2025
14. Bartke A, Darcy J. GH and ageing: pitfalls and new insights. Best Pract
Res Clin Endocrinol Metab. (2017) 31:113–25. doi: 10.1016/j.beem.2017.
02.005
15. Grimberg A, Allen DB. Growth hormone treatment for growth
hormone deficiency and idiopathic short stature: new guidelines
shaped by the presence and absence of evidence. Curr Opin
Pediatr. (2017) 29:466–71. doi: 10.1097/MOP.0000000000
000505
16. Moller-Madsen B, Thorlacius-Ussing O. Accumulation of mercury
in the anterior pituitary of rats following oral or intraperitoneal
administration of methyl mercury. Virchows Arch B Cell
Pathol Incl Mol Pathol. (1986) 51:303–11. doi: 10.1007/BF028
99039
17. Danscher G, Horsted-Bindslev P, Rungby J. Traces of mercury in organs
from primates with amalgam fillings. Exp Mol Pathol. (1990) 52:291–9.
doi: 10.1016/0014-4800(90)90070-T
18. Rice KM, Walker EM Jr., Wu M, Gillette C, Blough ER. Environmental
mercury and its toxic effects. J Prev Med Public Health. (2014) 47:74–83.
doi: 10.3961/jpmph.2014.47.2.74
19. Ahlmark A. Poisoning by methyl mercury compounds. Br J Ind Med. (1948)
5:117–9. doi: 10.1136/oem.5.3.117
20. Kosta L, Byrne AR, Zelenko V. Correlation between selenium and mercury
in man following exposure to inorganic mercury. Nature. (1975) 254:238–9.
doi: 10.1038/254238a0
21. Nylander M. Mercury in pituitary glands of dentists. Lancet. (1986) 1:442.
doi: 10.1016/S0140-6736(86)92395-0
22. Nylander M, Weiner J. Mercury and selenium concentrations and their
interrelations in organs from dental staff and the general population. Br J Ind
Med. (1991) 48:729–34. doi: 10.1136/oem.48.11.729
23. Cornett CR, Ehmann WD, Wekstein DR, Markesbery WR. Trace elements in
Alzheimer’s disease pituitary glands. Biol Trace Elem Res. (1998) 62:107–14.
doi: 10.1007/BF02820026
24. Nylander M, Friberg L, Eggleston D, Bjorkman L. Mercury accumulation in
tissues from dental staff and controls in relation to exposure. Swed Dent J.
(1989) 13:235–43.
25. Weiner JA, Nylander M. The relationship between mercury
concentration in human organs and different predictor variables.
Sci Total Environ. (1993) 138:101–15. doi: 10.1016/0048-9697(93)9
0408-X
26. Guzzi G, Grandi M, Cattaneo C, Calza S, Minoia C, Ronchi
A, et al. Dental amalgam and mercury levels in autopsy tissues:
food for thought. Am J Forensic Med Pathol. (2006) 27:42–5.
doi: 10.1097/01.paf.0000201177.62921.c8
27. Bjorkman L, Lundekvam BF, Laegreid T, Bertelsen BI, Morild I, Lilleng P,
et al. Mercury in human brain, blood, muscle and toenails in relation to
exposure: an autopsy study. Environ Health. (2007) 6:30. doi: 10.1186/1476-06
9X-6-30
28. Danscher G, Stoltenberg M, Juhl S. How to detect gold,
silver and mercury in human brain and other tissues by
autometallographic silver amplification. Neuropathol Appl
Neurobiol. (1994) 20:454–67. doi: 10.1111/j.1365-2990.1994.tb0
0996.x
29. Danscher G, Rungby J. Differentiation of histochemically visualized
mercury and silver. Histochem J. (1986) 18:109–14. doi: 10.1007/BF016
75364
30. Pamphlett R, Png FY. Shrinkage of motor axons following systemic
exposure to inorganic mercury. J Neuropathol Exp Neurol. (1998) 57:360–6.
doi: 10.1097/00005072-199804000-00009
31. Sondergaard LG, Brock B, Stoltenberg M, Flyvbjerg A,
Schmitz O, Smidt K, et al. Zinc fluxes during acute and
chronic exposure of INS-1E cells to increasing glucose levels.
Horm Metab Res. (2005) 37:133–9. doi: 10.1055/s-2005-8
61290
32. Danscher G, Stoltenberg M, Kemp K, Pamphlett R. Bismuth
autometallography: protocol, specificity, and differentiation. J
Histochem Cytochem. (2000) 48:1503–10. doi: 10.1177/0022155400048
01107
33. Nunes MA, Voss M, Corazza G, Flores EM, Dressler VL. External
calibration strategy for trace element quantification in botanical samples
by LA-ICP-MS using filter paper. Anal Chim Acta. (2016) 905:51–7.
doi: 10.1016/j.aca.2015.11.049
34. Clarkson TW. The toxicology of mercury. Crit Rev Clin
Lab Sci. (1997) 34:369–403. doi: 10.3109/104083697089
98098
35. Thorlacius-Ussing O, Moller-Madsen B, Danscher G. Intracellular
accumulation of mercury in the anterior pituitary of rats exposed to mercuric
chloride. Exp Mol Pathol. (1985) 42:278–86. doi: 10.1016/0014-4800(85)
90034-6
36. Bridges CC, Zalups RK. Mechanisms involved in the transport
of mercuric ions in target tissues. Arch Toxicol. (2017) 91:63–81.
doi: 10.1007/s00204-016-1803-y
37. Mitrofanova LB, Konovalov PV, Krylova JS, Polyakova VO, Kvetnoy
IM. Plurihormonal cells of normal anterior pituitary: facts and
conclusions. Oncotarget. (2017) 8:29282–99. doi: 10.18632/oncotarget.
16502
38. Bernhoft RA. Mercury toxicity and treatment: a review of the literature.
J Environ Public Health. (2012) 2012:460508. doi: 10.1155/2012/
460508
39. Thorlacius-Ussing O, Moller Graabaek P. Simultaneous ultrastructural
demonstration of heavy metals (silver, mercury) and acid
phosphatase. Histochem J. (1986) 18:639–46. doi: 10.1007/BF016
75299
40. Lawrence RE, Zoncu R. The lysosome as a cellular centre for signalling,
metabolism and quality control. Nat Cell Biol. (2019) 21:133–42.
doi: 10.1038/s41556-018-0244-7
41. Zhu X, Kusaka Y, Sato K, Zhang Q. The endocrine disruptive
effects of mercury. Environ Health Prev Med. (2000) 4:174–83.
doi: 10.1007/BF02931255
Frontiers in Endocrinology | www.frontiersin.org 9 June 2019 | Volume 10 | Article 419
Pamphlett et al. Mercury in Aging Pituitary Somatotrophs
42. Rudman D, Feller AG, Cohn L, Shetty KR, Rudman IW, Draper
MW. Effects of human growth hormone on body composition in
elderly men. Horm Res. (1991) 36(Suppl. 1):73–81. doi: 10.1159/0001
82193
43. Park JS, Ha KH, He K, Kim DJ. Association between
blood mercury level and visceral adiposity in adults.
Diabetes Metab J. (2017) 41:113–20. doi: 10.4093/dmj.2017.
41.2.113
44. Pamphlett R, Bishop DP, Kum Jew S, Doble PA. Age-related
accumulation of toxic metals in the human locus ceruleus.
PLoS ONE. (2018) 13:e0203627. doi: 10.1371/journal.pone.02
03627
45. Streets DG, Devane MK, Lu Z, Bond TC, Sunderland EM, Jacob DJ. All-time
releases of mercury to the atmosphere from human activities. Environ Sci
Technol. (2011) 45:10485–91. doi: 10.1021/es202765m
46. Ralston NV, Raymond LJ. Dietary selenium’s protective effects
against methylmercury toxicity. Toxicology. (2010) 278:112–23.
doi: 10.1016/j.tox.2010.06.004
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Pamphlett, Kum Jew, Doble and Bishop. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Endocrinology | www.frontiersin.org 10 June 2019 | Volume 10 | Article 419
